In a recent press release, GeoVax shared progress on their MPOX Vaccine and published a PowerPoint related to the their planned upcoming MonkeyPox related trial..
The planned Phase 3 immuno-bridging arm of the clinical trial is expected to enroll approximately 500 participants and evaluate neutralizing antibody responses relative to the approved MVA-based comparator vaccine from Bavarian Nordic (BVRNY). This study design intentionally provides rapid clinical validation, further de-risking the program in addition to the expedited development pathway.
They recently announced positive Scientific Advice from the European Medicines Agency supporting a Phase 3 immunobridging pathway toward potential regulatory approval. This pivotal Phase III trial is scheduled to initiate in Q4 ’26, with data results anticipated by mid-2027. 500 patients.
Bavarian Nordic was on our Watch List from $7.60 to $12.25, when they received a takeout valuing it at $3.1 billion. The deal later was voted down.
Our 4th Billion Dollar Takeover!
ESTIMATED REVENUES OF JYNNEOS FROM BAVARIAN NORDIC
Breakdown in US Dollars
- 2019–2021 (Initial Baseline): $230 million – $310 million
(Converted at a multi-year average of ~0.155 USD per DKK). Initial early bulk substance shipments and smallpox/mpox preparedness supplies to the U.S. and European nations generated DKK 1.5 billion to 2 billion total. - 2022 (Initial Mpox Outbreak): $241 million
(Converted at the 2022 annual average of 0.1416 USD per DKK). Outbreak emergency demand elevated vaccine specific revenue to DKK 1.7 billion out of the company’s total DKK 3 billion revenue pool. - 2023 (Peak Global Surge): $1.19 billion
(Converted at the 2023 annual average of 0.1452 USD per DKK). Global emergency stockpiling fueled peak sales of DKK 8.2 billion, representing the absolute highest single year of revenue for the vaccine. - 2024 (Commercial Launch & Transition): $377 million
(Converted at the 2024 annual average of 0.1451 USD per DKK). Driven by a private commercial launch in the U.S. and filling private distribution supply pipelines, Jynneos stabilized at DKK 2.6 billion. - 2025 (Sustained Contracts): $470 million
(Converted at the 2025 annual average of 0.1515 USD per DKK). Continued public preparedness procurement, including large UNICEF/Gavi defense supply agreements, netted DKK 3.1 billion. - 2026 (Year-to-Date Contract Backlog): $311 million
(Converted at the mid-2026 spot rate of 0.1556 USD per DKK). Bavarian Nordic has already locked in DKK 2 billion in public preparedness orders, which includes freeze-dried supply expansions with BARDA. [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]
Total Estimated Lifetime Revenues
Summing the individual historical dollar values reveals that Jynneos has generated roughly $2.82 billion to $2.90 billion in aggregate revenue directly for Bavarian Nordic Investor Relations over its entire lifespan.
From our AI Analyst: If you would like, I can extract the specific U.S. government BARDA contract amounts to show exactly how much of this revenue came directly from the United States. Would that detail help your analysis?
The U.S. Biomedical Advanced Research and Development Authority (BARDA) has been the single largest financial driver of Jynneos revenue. Since the vaccine’s original 2019 approval, BARDA has awarded over $1 billion in targeted contracts and options to transition the U.S. national stockpile from liquid-frozen doses to a longer-lasting, freeze-dried formulation. [1, 2]
The specific contract values and options exercised by BARDA between 2019 and early 2026 break down chronologically as follows:
Chronological BARDA Contract Breakdown [1]
- 2020 (Stockpile Expansion Order): $200 Million Total
- $106 million secured in April 2020 for bulk vaccine manufacturing and liquid-frozen doses recognized primarily in 2020.
- $83 million option exercised in December 2020 for more bulk vaccine invoiced in 2021.
- $12 million option for additional liquid-frozen doses finalized in late 2021.
- 2022 (Outbreak Conversion Phase): $119 Million
- Triggered during the initial global outbreak wave, this option funded the conversion of raw bulk vaccine into the first major batch of roughly 13 million freeze-dried doses.
- 2023 (Outbreak Replenishment): $120 Million
- Awarded in August 2023 to replace the massive amounts of bulk inventory depleted by the emergency manufacture of 5.5 million liquid-frozen doses during the global mpox health emergency.
- 2024 (Post-Outbreak Stockpile Security): $156.8 Million
- BARDA awarded this contract to replenish U.S. strategic reserves. $139.7 million directly covered the raw vaccine bulk product, while $17 million was allocated for storage services spanning 2025–2027.
- 2025 (Extended Shelf-Life Transition): $143.6 Million
- Following the FDA approval of the freeze-dried formulation, BARDA exercised options to fund the physical supply conversion of previous bulk and trigger milestone payments for successfully achieving an extended shelf life.
- 2026 (Recent Multi-Year Commitment): $97 Million
Total Direct BARDA Funding (Post-2019)
The combined value of these discrete contract actions brings total direct BARDA commitments to roughly $836 million. When accounting for the multi-year development awards attached to the underlying 10-year master agreement (originally signed in 2017), BARDA’s long-term capital backing represents the structural core of Bavarian Nordic’s Public Preparedness Portfolio. [1, 2, 3, 4]
WHY THE TAKEOVER FAILED
If a private equity takeover of Bavarian Nordic had been successful, the gross transaction amount would have been $3.1 billion to $3.2 billion (approximately DKK 20 to 21 billion). [1, 2]
The company was the target of a high-profile, multi-month corporate buyout attempt. The financial timeline of that failed takeover attempt progressed through two primary offers: [1, 2]
The Takeover Bid Financial Breakdown
- The Initial Agreed Offer (July 2025): $2.99 Billion
A private equity consortium consisting of Nordic Capital and Permira reached an initial agreement with Bavarian Nordic’s board to take the company private. They offered DKK 233 per share in cash, which valued the total transaction equity at roughly DKK 19 billion ($2.99 billion). - The Final Sweeter Offer (October 2025): $3.2 Billion
Because the company’s largest institutional shareholder (the Danish pension fund ATP) and retail investors strongly blocked the deal, the consortium raised its bid. They increased the offer price to DKK 250 per share. This adjustment pushed the potential gross value of the takeover to roughly DKK 20.5 billion ($3.2 billion). [1, 2, 3, 4, 5]
Despite the sweetened terms and unanimous backing from Bavarian Nordic’s board of directors, the takeover officially collapsed in November when it failed to secure the necessary two-thirds shareholder approval. Major institutional blocks argued that the private equity firms were undervaluing the company, specifically failing to account for the long-term, multi-billion-dollar recurring pipeline generated by the Jynneos vaccine. [1, 2]
The collapse of this multi-billion dollar deal directly resulted in structural leadership changes, with the CEO stepping down
And We Have a $26.4 Billion Winning Trifecta!
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. GeoVax is a client of Institutional Analyst, the publisher of the Biotech Stock Review and has been retained with a combination of cash and equity for ongoing progress, news coverage and research reporting for five thousand dollars per month.
Company Contact:
info@geovax.com
678-384-7220
Media Contact:
Jessica Starman
media@geovax.com
